Skip to main content
Download PDF
Download ePub

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program

Cardiovascular Diabetology volume 22, Article number: 66 (2023) Cite this article

Abstract

Background

Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide/ glucagon-like peptide-1 receptor agonist, is approved in the United States, Europe and Japan for the treatment of type 2 diabetes. Across the SURPASS-1 to -5 clinical studies, tirzepatide 5, 10 and 15 mg demonstrated significant improvements in glycated haemoglobin A1c (HbA1c) (− 1.9 to − 2.6%), body weight (− 6.6 to − 13.9%) and systolic blood pressure (SBP) (− 2.8 to − 12.6 mmHg) at the end of study treatment.

Methods

Post-hoc mediation analyses were conducted to evaluate weight-loss dependent and weight-loss independent effects of tirzepatide on SBP reductions across the 5 SURPASS studies. The safety population (all randomized patients who took at least 1 dose of study drug) of each study was analyzed. Additional analyses were conducted at individual study level or pooled across 5 SURPASS trials.

Results

The difference in mean SBP change from baseline at 40 weeks (total effect) between the tirzepatide and comparator groups was − 1.3 to − 5.1 mmHg (tirzepatide 5 mg), − 1.7 to − 6.5 mmHg (tirzepatide 10 mg) and − 3.1 to − 11.5 mmHg (tirzepatide 15 mg). These SBP reductions were primarily mediated through weight loss, with different degrees of contributions from weight-loss independent effects across the different trials. In the SURPASS-4 study, which enrolled patients with established cardiovascular disease, weight-loss independent effects explained 33% to 57% of difference in SBP change between tirzepatide and insulin glargine groups. In a pooled analysis of the SURPASS-1 to -5 studies, there was a significant (p < 0.001) but weak correlation (r = 0.18 to 0.22) between change in body weight and SBP. Reductions in SBP with tirzepatide were not dependent on concomitant antihypertensive medications at baseline as similar reductions were observed whether participants were receiving them or not (interaction p = 0.77). The largest SBP reductions were observed in the highest baseline category (> 140 mmHg), while those in the first quartile of baseline SBP category (< 122 mmHg) observed no further decrease in SBP.

Conclusions

Tirzepatide-induced SBP reduction was primarily mediated through weight loss, with different degrees of contributions from weight-loss independent effects across the different trials. SBP reduction was not dependent on antihypertensive medication use but dependent on baseline SBP value, alleviating theoretical concerns of hypotension.

Introduction

Hypertension is a common comorbidity of type 2 diabetes (T2D) and is twice as prevalent in people with T2D compared with those without T2D [1]. Approximately half of adults with hypertension are unaware they have it and, of those with hypertension, only 42% are treated while only 21% have their hypertension under control [2]. Hypertension is a strong risk factor for microvascular and macrovascular diabetic complications, including retinopathy, nephropathy and atherosclerotic cardiovascular disease [3, 4]. The American Diabetes Association recommends that patients with T2D should achieve a blood pressure (BP) goal of less than 140/90 mmHg. For patients with a high risk of cardiovascular (CV) disease, however, they recommend a BP below 130/80 mmHg [5]. Meanwhile, the European Society of Cardiology and the European Association for the Study of Diabetes recommend a BP target of 120–130/70–80 mmHg [6].

A glucose lowering agent with clinically relevant improvements in BP and cardiovascular risk reduction may be advantageous to the majority of patients with T2D. Some glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated CV benefits, [7,8,9,10] and generally a neutral to modest reduction in BP, making them a preferred treatment option in patients with T2D with indicators of high-risk of established atherosclerotic CV disease [11]. Even small reductions of 2.4 mmHg in systolic blood pressure (SBP) can have a significant effect in reducing CV events [12], with larger SBP reductions demonstrating greater effects [13,14,15,16].

Tirzepatide, a once-weekly glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 RA, is approved in the United States, Europe and Japan for the treatment of people with T2D. In five global phase 3 clinical trials (SURPASS-1, -2, -3, -4, -5), tirzepatide produced substantial reductions in glycated haemoglobin A1c (HbA1c) (− 1.9 to − 2.6%), and body weight (− 6.6 to − 13.9%) over 40 to 52 weeks, enabling many people (23–52%) with T2D to achieve normalization of glucose control (defined as HbA1c < 5.7%) [17,18,19,20,21]. Across the SURPASS studies, tirzepatide 5, 10 and 15 mg also demonstrated clinically relevant improvements in SBP (− 2.8 to − 12.6 mmHg) over 40–52 weeks [17,18,19,20,21,22]. As weight loss is known to lower SBP, it is important to assess the contribution of tirzepatide-induced weight loss on SBP reduction [23].

Tirzepatide has a safety profile consistent with that of GLP-1 RAs, with mild to moderate gastrointestinal adverse events (AEs) mostly reported during the dose escalation period which decreased over time. Additionally, in a meta-analyses conducted across seven phase 2 and 3 clinical studies, tirzepatide demonstrated CV safety when compared with pooled comparators with the hazard ratio of 0.80 (95% confidence interval [CI]: 0.57, 1.11) for major adverse cardiovascular events (MACE-4) which included death due to CV cause, myocardial infarction, stroke and hospitalization for unstable angina [24].

The objective of this report is to provide an overview of the effect of tirzepatide on SBP across the five SURPASS studies and to assess the impact of weight loss and other select variables (use of antihypertensive medication and baseline SBP value) on this effect.

Materials and methods

Study design and participants

A database was created using 40/42-week clinical data from five randomized controlled trials, SURPASS-1, -2, -3, -4 and -5. A common 40/42-week primary time point was selected for consistent assessment across the five SURPASS studies. The study design for each trial is described in detail in Additional file 1. Key eligibility criteria, and primary efficacy and safety results have been published previously for all five trials [17,18,19,20,21] (ClinicalTrial.gov Identifiers: NCT03954834, NCT03987919, NCT03882970, NCT03730662, NCT04039503). Two of the trials were placebo-controlled (SURPASS-1 and -5) while the remaining three trials compared tirzepatide (5 mg, 10 mg and 15 mg) to semaglutide 1 mg, titrated insulin degludec and titrated insulin glargine (SURPASS-2, -3 and -4, respectively). Participants randomized to tirzepatide started at a 2.5 mg dose once weekly and escalated the dose by 2.5 mg every 4 weeks until they reached their assigned dose. Participants continued their baseline antihypertensive medications and were permitted to adjust during the study.

Body weight measurements were carried out in a consistent manner using a calibrated electronic scale in kilograms. All weights for a given patient were measured using the same scale and patients wore light clothes with no shoes while their weight was measured. All laboratory parameters were assessed in a central laboratory. Blood pressure and pulse rate were measured after the participant sat quietly for 5 min. For each parameter, two measurements were taken using the same arm with the recordings taken at least 1 min apart. BP was taken with an automated blood pressure machine.

Statistical analysis

Post-hoc mediation analyses were conducted to evaluate weight-loss dependent (WL-D) and weight-loss independent (WL-IND) effects of tirzepatide on SBP reductions across the five SURPASS studies individually and also pooled doses per study. The model for the estimation of WL-D and WL-IND effects on SBP at Week 40/42 included the interaction between treatment and weight change, with the baseline variable for SBP, use of antihypertensive drug, country and HbA1c category ([≤ 8.0%, > 8.0%] for SURPASS-5, [≤ 8.5%, > 8.5%] for other studies) as covariates in the model. The safety population (all randomly assigned patients who took at least one dose of study drug) of each study was used in this analysis which included data regardless of adherence to study drug or initiation, modification or discontinuation of antihypertensive medications. With the integrated database from the five studies, subgroup analyses of change from baseline in SBP by baseline antihypertensive drug use (Yes, No) was performed. Correlation between SBP change from baseline and weight change from baseline were performed and the Pearson correlation coefficient was presented. SBP change from baseline was summarized by the baseline SBP quartile.

Results

Baseline characteristics and key demographics

Patient demographics and baseline characteristics from participants randomized in SURPASS-1 to -5 (n = 4199; n = 1394 receiving tirzepatide 5 mg, n = 1397 receiving tirzepatide 10 mg, n = 1408 receiving tirzepatide 15 mg and n = 2064 receiving placebo or active comparators) are shown in Table 1. Blood pressure at baseline is also shown in Additional file 2. Baseline characteristics and demographics were well balanced between tirzepatide and comparators for each study and pooled dataset.

Table 1 Baseline characteristics and key demographics (SURPASS 1–5 individual [pooled arms] and pooled data)
Full size table

Across the SURPASS studies, mean age was 54–64 years and 47–94% of participants were using antihypertensive medications at baseline. At baseline, SURPASS-1 participants had the lowest SBP and duration of diabetes (127.6 mmHg and 5 years) compared to SURPASS-5 participants (137.9 mmHg and 13 years). As expected, SURPASS-4 participants had the highest prevalence of CV disease (87%), use of antihypertensive medication at baseline (94%) and lowest estimated glomerular filtration rate (81.3 mL/min/1.73m2), as this study enrolled patients with a high CV risk (coronary heart disease, peripheral arterial disease, cerebrovascular disease, chronic kidney disease or congestive heart failure). SURPASS-4 participants were also older and 63% were male.

Systolic blood pressure reduction with tirzepatide across SURPASS program

Across the SURPASS program, SBP reductions ranged from − 4.2 to − 12.6 mmHg in participants receiving tirzepatide. In each study, SBP reductions were greater with tirzepatide than with placebo or active comparator groups at Week 40/42.

In the monotherapy placebo-controlled study (SURPASS-1), treatment with tirzepatide 10 mg resulted in significantly greater SBP reductions compared with placebo (estimated treatment difference [ETD] [95% CI] − 3.1 [− 6.2, 0.1] mmHg; P = 0.04). In the add-on to basal insulin placebo-controlled study (SURPASS-5), all doses (5, 10 and 15 mg) resulted in significantly greater SBP reductions compared with placebo (ETD [95% CI] − 4.4 [− 7.8, − 1.0], − 6.6 [− 9.9, − 3.2] and − 10.9 [− 14.3, − 7.5] mmHg; P = 0.01, P < 0.001 and P < 0.001, respectively) (Fig. 1).

Fig. 1
figure 1

Change from baseline in systolic blood pressure at Week 40/42. Data are least-squares mean ± SE. Pooled comparator data are not presented as these comparators have varying effects on SBP. Data are taken from the safety population of each study. *p < 0.05 vs. placebo/active comparator, ***p < 0.001 vs. placebo/active comparator. CI confidence interval, SBP systolic blood pressure, SE standard error, TZP tirzepatide

Full size image

In the SURPASS-2 study, 10 mg and 15 mg dose groups of tirzepatide demonstrated significantly greater SBP reductions than semaglutide 1 mg (ETD [95% CI] − 1.8 [− 3.4, − 0.1] and − 3.0 [− 4.6, − 1.3] mmHg; P = 0.03 and P < 0.001, respectively), while in SURPASS-3 and SURPASS-4 studies, SBP reductions were greater with all tirzepatide doses compared with insulin degludec (ETD [95% CI] − 4.9 [− 6.8, − 3.0], − 6.3 [− 8.2, − 4.4], − 6.9 [− 8.8, − 5.0] mmHg) and insulin glargine (ETD [95% CI] − 4.7 [− 6.5, − 3.0], − 5.6 [− 7.4, − 3.9], − 7.2 [− 8.9, − 5.5] mmHg) for tirzepatide 5, 10 and 15 mg, respectively: P < 0.001) (Fig. 1).

Overall, SBP reductions were greater with tirzepatide than with placebo or active comparator groups and were dose dependent with the greatest SBP reductions observed in the tirzepatide 15 mg treatment groups. Similarly, pooled analysis across the five SURPASS trials at Week 40/42 indicated dose dependent SBP reductions of − 4.8, − 5.8 and − 7.0-mmHg for tirzepatide 5, 10 and 15 mg treatment groups, respectively. (Fig. 1).

Association between systolic blood pressure and weight change from baseline

There were similar reductions in body weight for all tirzepatide doses across the five SURPASS studies. Similar to SBP, mean body weight reductions at Week 40/42 were dose dependent, with the greatest reductions observed in the tirzepatide 15 mg treatment groups across the SURPASS program. (− 7.0, − 9.1 and − 10.8 kg for tirzepatide 5, 10 and 15 mg treatment groups, respectively). Body weight reductions did not reach a plateau.

The mediation analysis showed contribution of WL-D and WL-IND effects on total effect of SBP reductions presented as difference between tirzepatide and comparator group for each study (Fig. 2). For WL-D effects between tirzepatide and comparator groups, the ETD (95% CI) in mean SBP change from baseline ranged from − 1.0 (− 1.6, − 0.5) to − 4.5 (− 6.7, − 2.4) mmHg (tirzepatide 5 mg), − 2.0 (− 2.8, − 1.4) to − 6.2 (− 8.9, − 3.6) mmHg (tirzepatide 10 mg) and − 2.4 (− 3.3, − 1.6) to − 7.5 (− 10.6, − 4.4) mmHg (tirzepatide 15 mg) (Fig. 2). WL-IND effects contributed to a lesser extent as the ETD (95% CI) in mean SBP change from baseline between tirzepatide and comparator groups ranged from − 0.3 (− 1.8, 1.3) to − 3.8 (− 8.4, 0.9) mmHg (tirzepatide 5 mg), + 2.5 (− 1.4, 6.7) to − 2.9 (− 5.9, 0.1) mmHg (tirzepatide 10 mg) and + 0.7 (− 3.3, 4.8) to − 6.5 (− 10.8, − 1.9) mmHg (tirzepatide 15 mg) (Fig. 2). Mediation analysis conducted by pooling patients across all doses of tirzepatide within each study also showed consistent results (Additional file 3).

Fig. 2
figure 2

Mediation analyses for systolic blood pressure using weight loss as a factor at Week 40/42 (SURPASS 1–5 individual data). Data are least-squares mean ETD (95% CI). Data are taken from the safety population of each study. Percentage values represent the percent of blood pressure reduction mediated by weight loss. CI confidence interval, ETD estimated treatment difference, SBP systolic blood pressure, TZP tirzepatide, WL-D weight-loss dependent, WL-IND weight-loss independent

Full size image

In the SURPASS-4 study where patients with high CV risk were enrolled, and in the SURPASS-5 study where patients had the longest duration of T2D, WL-IND effects explained 33–57% and 26–73% of the difference in SBP change between tirzepatide versus the insulin glargine and placebo group, respectively (Fig. 2).

In the pooled analyses, there was a significant (p < 0.001) but weak correlation (r = 0.18 to 0.22) between change in body weight and SBP from baseline at Week 40/42 in tirzepatide-treated patients (Fig. 3).

Fig. 3
figure 3

Correlation between change in systolic blood pressure and body weight at Week 40/42. Data taken from the safety population of SURPASS 1–5 pooled. SBP systolic blood pressure, r correlation coefficient, TZP tirzepatide

Full size image

Subgroup analysis of systolic blood pressure change from baseline by use of antihypertensive medications

At baseline, in the pooled tirzepatide treatment groups, 72.4% of participants were receiving antihypertensive medications. Similarly, in the pooled comparator group, 78.1% were receiving antihypertensive medications at baseline. In the SURPASS-4 study which enrolled participants with established CV disease, 94% were receiving antihypertensive medications at baseline. (Table 1).

Reductions in SBP with tirzepatide were not dependent on concomitant antihypertensive medications as similar reductions were observed whether participants were receiving them or not (tirzepatide 5 mg, − 5.0 vs − 4.3 mmHg; tirzepatide 10 mg, − 5.7 vs − 5.8 mmHg; tirzepatide 15 mg, − 7.0 vs − 7.0 mmHg) with a non-significant treatment by antihypertensive medication (Yes, No) interaction (P = 0.77) (Fig. 4).

Fig. 4
figure 4

Change from baseline in systolic blood pressure at Week 40 by use of antihypertensive medication at baseline. Data taken from the safety population of SURPASS 1–5 pooled. SBP systolic blood pressure, r correlation coefficient, TZP tirzepatide

Full size image

Subgroup analysis of systolic blood pressure changes from baseline by quartile of baseline value

The fourth quartile of SBP baseline value was > 140 mmHg, the median was 132.0 mmHg and the first quartile was ≤ 122.5 mmHg. Quartile of baseline SBP value significantly influenced the SBP change at Week 40/42 (p < 0.0001) (Fig. 5). The greatest SBP change with tirzepatide doses, which ranged from − 14.0 to − 17.5 mmHg, was observed in participants with the highest SBP values at baseline (Q4, > 140 mmHg). SBP was significantly reduced in all categories, except for in the lowest SBP baseline value category (Q1, ≤ 122.5 mmHg), where no clinically meaningful changes were observed.

Fig. 5
figure 5

Change from baseline in systolic blood pressure at Week 40 by quartile of baseline value. Data are mean ± SE. Data taken from the safety population of SURPASS 1–5 pooled. N population size, SBP systolic blood pressure, SD standard deviation, TZP tirzepatide

Full size image

Body weight reduction was similar across all the quartiles of SBP baseline value (tirzepatide 5 mg − 6.8 kg to − 7.3 kg; tirzepatide 10 mg − 8.9 kg to − 9.4 kg; tirzepatide 15 mg − 10.3 kg to − 11.6 kg) (Fig. 5).

Safety assessment

Tirzepatide had a safety profile consistent with that of GLP-1 RAs with the majority of gastrointestinal AEs noted during the dose escalation period and decreasing overtime [17,18,19,20,21]. The most commonly reported gastrointestinal AEs were nausea and diarrhea. The percentage of patients reporting ≥ 1 treatment-emergent gastrointestinal AE by preferred term ranged from 3 to 16% for tirzepatide 5 mg, 3–24% for tirzepatide 10 mg and 6–24% for tirzepatide 15 mg across the SURPASS studies.

Treatment with tirzepatide resulted in a mean increase in heart rate of 1–4, 2–4 and 3–6 beats per minute (bpm) for 5-, 10- and 15-mg groups, respectively, at the end of study treatment (Week 40/42 for SURPASS-1, 2 and 5 and Week 52 for SURPASS-3 and 4). For the two placebo-controlled studies, heart rate increased by 0–2 bpm on average. Treatment with active comparators semaglutide 1 mg, insulin degludec and insulin glargine resulted in mean heart rate increases of 4, 1 and 1 bpm, respectively.

Discussion

Our findings in context

Tirzepatide demonstrated clinically significant improvements in SBP ranging from 4 to 13 mmHg reduction across the three doses (5 mg, 10 mg and 15 mg) at 40 weeks in the SURPASS clinical program. Tirzepatide 10 mg and 15 mg demonstrated statistically significant reductions in SBP compared to GLP-1 RA, semaglutide 1 mg (5.3 mmHg and 6.5 mmHg vs 3.6 mmHg, respectively). The magnitude of effect was also consistent in SURPASS 4 which enrolled patients with established cardiovascular disease.

We observed that the effect of tirzepatide on SBP was mediated through weight loss with different degrees of contributions from weight-loss independent effects across the different SURPASS trials. Furthermore, SBP reduction was not dependent on antihypertensive medication use but dependent on baseline SBP value.

These findings are in agreement with a pooled analysis of six randomized phase 3 clinical trials in GLP-1 RA liraglutide [25]. Similarly, the authors reported that SBP was weakly correlated with weight loss at 26 weeks and SBP reductions were observed in the presence and absence of antihypertensive medication. However, mediation analyses were not carried out across the trials to determine the extent of the weight-loss contribution, nor was the SBP change according to baseline values evaluated. In a meta-analysis conducted across 33 randomized studies, the authors evaluated GLP-1 RAs, liraglutide and exenatide, using random-effect analysis and concluded that these GLP-1 RAs induced a small but significant change in SBP that appeared to be independent of the degree of weight loss and SBP values at baseline [26].

The effect of weight loss and other variables on blood pressure

Weight loss of about 5–10% is expected to improve SBP by > 5 mmHg [27]. Across the SURPASS program, weight loss associated with tirzepatide explained the majority of treatment effect on SBP. Excess adiposity, insulin resistance, inflammation and higher oxidative stress are hallmarks of type 2 diabetes and obesity, which are proven to alter endothelial dysfunction and affect haemodynamics resulting in elevated blood pressure [28, 29]. It is not surprising that robust weight loss, reduction in liver and abdominal fat [30] and improvement in insulin sensitivity [31] associated with tirzepatide treatment may likely affect this key pathophysiological state associated with elevated BP in this population.

Nevertheless, there was some heterogeneity in this observation in the studies with higher baseline age, SBP, use of antihypertensive medications and duration of diabetes (SURPASS-4 and SURPASS-5) where weight loss explained roughly half of the total effect on SBP. Reduction in insulin usage in the SURPASS-5 study, particularly in the 15-mg dose group, may have also played a role in SBP reduction. There was a weak correlation between weight loss and SBP in the pooled analyses across SURPASS trials which further raises curiosity to explore potential weight-loss independent mechanisms that could be driving the reduction in SBP. These mechanisms are potentially not related to the study treatment. While the mediation analysis indicated the treatment effect on SBP reduction were mainly through the weight loss, the results of the two analyses are not contradictory. The lack of robust association between weight loss and improvement in SBP has been reported with GLP-1 RAs [24, 25]. Natriuresis [32], direct vasodilation [33], reductions in sympathetic nervous system activity [34], extracellular volume and midregional-pro-atrial natriuretic peptide (proANP) [33, 35] are potential direct mechanisms for GLP-1 RAs leading to SBP lowering.

To ascertain whether use of antihypertensive mediation impacts the degree of SBP reduction with tirzepatide, analyses were conducted for subgroups of patients using or not using antihypertensive medication at treatment initiation. These findings may be relevant for health care professionals initiating tirzepatide in patients with T2D using antihypertensive medications, as this could be a potential opportunity to adjust antihypertensive medications if target blood pressure is reached. SBP reduction with tirzepatide was highest (mean of 14–18 mmHg) in patients with a baseline value greater than 140 mmHg while there was minimal impact on SBP for patients with a baseline value of less than 123 mmHg. This is a clinically relevant finding from a patient safety perspective as this effect minimizes any potential risk of hypotension or syncope. This finding is also consistent with that reported with liraglutide [36].

Although much is known about the effects of GLP-1 RAs on blood pressure, little clinical data are available on the effects of GIP agonism. After a 6-day subcutaneous GIP infusion in patients with type 1 diabetes, a 4.6 mmHg reduction in SBP was noted [37]. In a separate study on patients with T2D already using GLP-1 RA and metformin, continuous acute infusion of GIP (6 pmol/kg/min) resulted in significant reduction in SBP compared to placebo. This effect was hypothesized to be due to elevated proANP and suggests an additive haemodynamic effect of GIP and GLP-1 receptor co-agonism [38]. Superior SBP lowering with tirzepatide compared to semaglutide may be due to greater weight loss or partly due to GIP specific mechanisms that warrant further exploration.

Safety

Across SURPASS studies, tirzepatide was associated with an increase in heart rate of 1 to 6 beats per minute at the end of study treatment. There was no significant difference between tirzepatide and semaglutide in the SURPASS-2 study at Week 40 in change in heart rate compared to baseline despite higher reduction in HbA1c, weight and SBP [18]. Several mechanisms have been postulated for elevation in heart rate with GLP-1 RAs, such as reflex tachycardia, increase in sympathetic nervous system activity and direct sino-atrial node action but none have been clinically proven yet [39]. Several long-acting GLP-1 RAs have demonstrated CV protection in a dedicated CV outcome trial (CVOT) [7,8,9,10, 38] while the SURPASS-CVOT study (NCT04255433) for tirzepatide is ongoing and will provide further insights into whether these effects on blood pressure lowering, improvements in metabolic parameters and elevation in heart rate would combine to produce any meaningful impact on hard CV outcomes. To date, tirzepatide has demonstrated CV safety when compared with pooled comparators in a meta-analysis of phase 2 and phase 3 studies with the hazard ratio of 0.80 (95% CI: 0.57–1.11) for MACE-4 [24]. In a post-hoc analysis of SURPASS-4 data, tirzepatide slowed the rate of decline in eGFR, showed clinically meaningful improvement in albuminuria and significantly lowered occurrence of the composite kidney outcomes compared to insulin glargine which may be related to SBP lowering [40].

Limitations and conclusions

The limitations of this study include its post-hoc nature and the fact we did not systematically collect indications for antihypertensive medications as these could have been used for other co-morbidities. Studies were not designed to systematically assess blood pressure and randomization was not stratified based on baseline status of hypertension, SBP and other relevant parameters that could have affected the outcomes. Weight loss with tirzepatide did not plateau at 40/42 weeks and therefore longer term data could provide more robust assessments in future.

In conclusion, tirzepatide has demonstrated clinically relevant reductions in SBP across the SURPASS program. This effect was primarily mediated through weight loss, with different degrees of contributions from weight-loss independent effects across the different SURPASS trials. Furthermore, SBP reduction was not dependent on antihypertensive medication use and dependent on baseline SBP value, alleviating theoretical concerns of hypotension in patients with lower baseline SBP.

Availability of data and materials

Lilly provides access to all individual participant data collected during the trial, after anonymization, with the exception of pharmacokinetic or genetic data. Data are available to request 6 months after the indication studied has been approved in the US and EU and after primary publication acceptance. No expiration date of data requests is currently set once they are made available. Access is provided after a proposal has been approved by an independent review committee identified for this purpose and after receipt of a signed data sharing agreement. Data and documents, including the study protocol, statistical analysis plan, clinical study report, blank or annotated case report forms, will be provided in a secure data sharing environment for up to 2 years per proposal. For details on submitting a request, see the instructions provided at vivli.org.

Abbreviations

AE:

Adverse event

BMI:

Body mass index

BP:

Blood pressure

CI:

Confidence interval

CV:

Cardiovascular

CVOT:

Cardiovascular outcome trial

DBP:

Diastolic blood pressure

ETD:

Estimated treatment difference

GIP:

Glucose-dependent insulinotropic polypeptide

GLP-1 RA:

Glucagon-like peptide-1 receptor agonist

HbA1c:

Glycated haemoglobin A1c

MACE-4:

Major adverse cardiovascular events

proAND:

Pro-atrial natriuretic peptide

SBP:

Systolic blood pressure

T2D:

Type 2 diabetes

WL-D:

Weight-loss dependent

WL-IND:

Weight-loss independent

References

  1. Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: clinical insights and vascular mechanisms. Can J Cardiol. 2018;34(5):575–84.

    Article  PubMed  Google Scholar 

  2. Organisation WH. Hypertension—Key facts. 2021.

  3. Arambewela MH, et al. Prevalence of chronic complications, their risk factors, and the cardiovascular risk factors among patients with type 2 diabetes attending the diabetic clinic at a Tertiary Care Hospital in Sri Lanka. J Diabetes Res. 2018;2018:4504287.

    Article  PubMed  PubMed Central  Google Scholar 

  4. de Boer IH, et al. Diabetes and hypertension: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(9):1273–84.

    Article  PubMed  Google Scholar 

  5. American Diabetes Association Professional Practice C. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022; 45(Suppl 1): S144–S174.

  6. Cosentino F, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323.

    Article  PubMed  Google Scholar 

  7. Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet. 2019;394(10193):121–30.

    Article  CAS  Google Scholar 

  8. Hernandez AF, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. The Lancet. 2018;392(10157):1519–29.

    Article  CAS  Google Scholar 

  9. Marso SP, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.

    Article  CAS  PubMed  Google Scholar 

  10. Marso SP, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. American Diabetes Association Professional Practice C et al. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2022. Diabetes Care. 2022; 45(Suppl 1): S125–S143.

  12. Gerstein HC, Mann JF, Hoogwerf B, Zinman B, Held C, Fisher M, Wolffenbuttel B, Bosch J, Richardson L, Pogue J, Heart Outcomes Prevention Evolution (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–9.

    Article  CAS  Google Scholar 

  13. Emdin CA, et al. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA. 2015;313(6):603–15.

    Article  PubMed  Google Scholar 

  14. Ettehad D, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. The Lancet. 2016;387(10022):957–67.

    Article  Google Scholar 

  15. Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352: i717.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Rahimi K, et al. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. The Lancet. 2021;397(10285):1625–36.

    Article  Google Scholar 

  17. Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. 2021;398(10295):143–55.

    Article  CAS  Google Scholar 

  18. Frías JP, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021;385(6):503–15.

    Article  PubMed  Google Scholar 

  19. Ludvik B, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet. 2021;398(10300):583–98.

    Article  CAS  Google Scholar 

  20. Del Prato S, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet. 2021;398(10313):1811–24.

    Article  Google Scholar 

  21. Dahl D, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022;327(6):534–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Nauck MA, D’Alessio DA. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022;21(1):169.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Hall ME, et al. Weight-loss strategies for prevention and treatment of hypertension: a scientific statement from the American Heart Association. Hypertension. 2021;78(5):e38–50.

    Article  CAS  PubMed  Google Scholar 

  24. Sattar N, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Fonseca VA, et al. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complications. 2014;28(3):399–405.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Katout M, et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. Am J Hypertens. 2014;27(1):130–9.

    Article  CAS  PubMed  Google Scholar 

  27. Hall ME, Faha M, Cohen JB, Ard JD, Egan BM, Hall JE, Lavie CJ, Ma J, Ndumele CE, Schauer PR, Shimbo D, on behalf of the American Heart Association Council on Hypertension; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; and Stroke Council. Weight-loss strategies for prevention and treatment of hypertension: a scientific statement from the American Heart Association. Hypertension. 2021;78(5):e38–50.

    Article  CAS  PubMed  Google Scholar 

  28. Furukawa S, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004;114(12):1752–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Sironi AM, et al. Visceral fat in hypertension: influence on insulin resistance and beta-cell function. Hypertension. 2004;44(2):127–33.

    Article  CAS  PubMed  Google Scholar 

  30. Gastaldelli A, et al. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10(6):393–406.

    Article  CAS  PubMed  Google Scholar 

  31. Heise T, et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022;10(6):418–29.

    Article  CAS  PubMed  Google Scholar 

  32. Ussher JR, et al. Cardiovascular effects of incretin-based therapies: integrating mechanisms with cardiovascular outcome trials. Diabetes. 2022;71(2):173–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Gaspari T, et al. A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE−/− mouse model. Diab Vasc Dis Res. 2011;8(2):117–24.

    Article  PubMed  Google Scholar 

  34. van Ruiten CC, et al. Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial. Cardiovasc Diabetol. 2022;21(1):63.

    Article  PubMed  PubMed Central  Google Scholar 

  35. von Scholten BJ, et al. Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. Diabet Med. 2015;32(3):343–52.

    Article  Google Scholar 

  36. Wijkman MO, et al. Predictors and correlates of systolic blood pressure reduction with liraglutide treatment in patients with type 2 diabetes. J Clin Hypertens (Greenwich). 2019;21(1):105–15.

    Article  CAS  PubMed  Google Scholar 

  37. Christensen MB, Filip K. Six-day subcutaneous GIP infusion increases glycemic time-in-range in patients with type 1 diabetes. Diabetes. 2020;69:351.

    Article  Google Scholar 

  38. Sorum N, et al. GIP infusion acutely decreases blood pressure and increases heart rate in men with type 2 diabetes, concomitantly with increased proatrial natriuretic peptide levels. In: Diabetologia. 2022; Springer, USA.

  39. Heuvelman VD, Van Raalte DH, Smits MM. Cardiovascular effects of glucagon-like peptide 1 receptor agonists: from mechanistic studies in humans to clinical outcomes. Cardiovasc Res. 2020;116(5):916–30.

    Article  CAS  PubMed  Google Scholar 

  40. Heerspink HJL, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022;10(11):774–85.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Eli Lilly and Company would like to thank the clinical trial participants and their caregivers, without whom this work would not be possible.

Funding

Funded by Eli Lilly and Company.

Author information

Authors and Affiliations

  1. University of Texas Southwestern Medical Center, Dallas, TX, USA

    Ildiko Lingvay

  2. Diabetes Unit, Department of Endocrinology and Metabolism, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel

    Ofri Mosenzon

  3. Eli Lilly and Company, Indianapolis, IN, USA

    Katelyn Brown, Xuewei Cui, Ciara O’Neill, Laura Fernández Landó & Hiren Patel

Authors
  1. Ildiko Lingvay
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ofri Mosenzon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katelyn Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xuewei Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ciara O’Neill
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Laura Fernández Landó
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hiren Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

HP contributed to the conception of the work. LFL contributed to the design of the work. XC analysed the data. HP, CON, IL, KB, LFL, OM interpreted the data. HP and CON drafted the manuscript and all authors critically revised. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Hiren Patel.

Ethics declarations

Consent for publication

All authors consent to publication.

Competing interests

Ildiko Lingvay received research funding (paid to institution) from Novo Nordisk, Sanofi, Merck, Pfizer, Mylan and Boehringer Ingelheim. She received advisory/consulting fees and/or other support from: Novo Nordisk, Eli Lilly and Company, Sanofi, AstraZeneca, Boehringer Ingelheim, Janssen, Intercept, Intarcia, Target Pharma, Merck, Pfizer, Novartis, GI Dynamics, Mylan, Mannkind, Valeritas, Zealand Pharma, Shionogi, Carmot and Bayer. Ofri Mosenzon has received research grant support through Hadassah Hebrew University Hospital, Novo Nordisk and AstraZeneca. She received advisory/consulting fees and/or other support from Novo Nordisk, Eli Lilly and Company, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, Novartis, AstraZeneca and BOL Pharma. She is on the speaker’s bureau for Novo Nordisk, Eli Lilly and Company, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, AstraZeneca and Janssen. Katelyn Brown, Xuewei Cui, Ciara O’ Neill, Laura Fernández Landó and Hiren Patel are employees and shareholders of Eli Lilly and Company.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1

: Summary of the SURPASS 1–5 study designs.

Additional file 2

: Baseline blood pressure across SURPASS studies.

Additional file 3

: Mediation analyses for systolic blood pressure using weight loss as a factor at Week 40/42 (SURPASS 1–5, pooled data for TZP dose).

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lingvay, I., Mosenzon, O., Brown, K. et al. Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program. Cardiovasc Diabetol 22, 66 (2023). https://doi.org/10.1186/s12933-023-01797-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12933-023-01797-5

Keywords

Cardiovascular Diabetology

ISSN: 1475-2840